Table 3 A comparison between group A and group B.
Group A (n = 46) | Group B (n = 48) | P value | |
|---|---|---|---|
ONL change (µm)‡ | − 1.3 ± 8.9 | + 21.5 ± 9.0 | < 0.001* |
Number of injections | 7.3 ± 3.8 | 6.9 ± 3.7 | 0.621* |
Duration of symptom (days) | 36.5 ± 42.8 | 34.5 ± 93.6 | 0.903* |
PVD status (with/without) | 20/23 | 18/18 | 0.823 |
BCVA (logMAR) | |||
Baseline | 0.51 ± 0.24 | 0.45 ± 0.31 | 0.250* |
After 3 loading doses | 0.41 ± 0.24 | 0.27 ± 0.25 | 0.010* |
At 1-year | 0.43 ± 0.27 | 0.22 ± 0.19 | < 0.001* |
ONL thickness (μm) | |||
Baseline | 53.0 ± 22.7 | 56.3 ± 15.9 | 0.404* |
After 3 loading doses | 51.6 ± 21.8 | 77.9 ± 18.1 | < 0.001* |
At 1-year | 56.7 ± 26.8 | 69.6 ± 20.0 | 0.010* |
SRF height (μm) | |||
Baseline | 165.6 ± 84.0 | 178.2 ± 110.7 | 0.350* |
After 3 loading doses | 37.3 ± 44.8 | 19.0 ± 38.9 | 0.046* |
At 1-year | 64.1 ± 89.9 | 49.8 ± 65.9 | 0.377* |
CNV location | 0.012† | ||
Subfovea | 35 (76.0%) | 23 (45.5%) | |
Juxtafovea (< 1 mm diameter circle) | 10 (20.0%) | 20 (45.5%) | |
Parafovea (> 1 mm diameter circle) | 1 (4.0%) | 5 (9.0%) | |
